Human immunodeficiency virus type 1 group M protease in Cameroon: Genetic diversity and protease inhibitor mutational features

被引:41
作者
Fonjungo, PN
Mpoudi, EN
Torimiro, JN
Alemnji, GA
Eno, LT
Lyonga, EJ
Nkengasong, JN
Lal, RB
Rayfield, M
Kalish, ML
Folks, TM
Pieniazek, D
机构
[1] CDCP, Div AIDS STD & TB Lab Res, Natl Ctr Infect Dis, HIV & Retrovirol Branch, Atlanta, GA 30333 USA
[2] CDCP, Div AIDS STD & TB Lab Res, Natl Ctr Infect Dis, HIV Immunol & Diagnost Branch, Atlanta, GA 30333 USA
[3] CDCP, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA
[4] Hop Mil Yaounde, Yaounde, Cameroon
[5] Projet RETRO CI, Abidjan, Cote Ivoire
关键词
D O I
10.1128/JCM.40.3.837-845.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
To establish a baseline for monitoring resistance to protease inhibitors (PIs) and examining the efficacy of their use among persons in Cameroon infected with human immunodeficiency virus type 1 (HIV-1), we analyzed genetic variability and PI resistance-associated substitutions, in PCR-amplified protease (PR) sequences in strains isolated from 110 HIV-1-infected, drug-naive Cameroonians. Of the 110 strains, 85 were classified into six HIV-1 PR subtypes, A (n = 1), B (n = 1), F (n = 4), G (n = 7), H (n = 1), and J (n = 7), and a circulating recombinant form, CRF02-AG (n = 64). PR genes from the remaining 25 (23%) specimens were unclassifiable, whereas 2% (7 of 301) unclassifiable PR sequences were reported for a global collection. Two major PI resistance-associated mutations, 20M and 241, were detected in strains from only two specimens, whereas secondary mutations were found in strains from all samples except one strain of subtype B and two strains of CRF02-AG. The secondary mutations showed the typical PI resistance-associated pattern for non-subtype B viruses in both classifiable and unclassifiable PR genes, with 361 being the predominant (99%) mutation, followed by 63P (18%), 20R (15%), 771 (13%), and 10I or 10V (11%). Of these mutations, dual and triple PI resistance-associated substitutions were found in 38% of all the Cameroonian strains. Compared with classifiable PR sequences, unclassifiable, sequences had significantly more dual and triple substitutions (64% versus 30%; P = 0.004). Phenotypic and clinical evaluations are needed to estimate whether PI resistance during antiretroviral drug treatment occurs more rapidly in individuals infected with HIV-1 strains harboring multiple PI resistance-associated substitutions. This information may be important for determination of appropriate drug therapies for HIV-1-infected persons in Cameroon, where more than one-third of HIV-1 strains were found to carry dual and triple minor PI resistance-associated mutations.
引用
收藏
页码:837 / 845
页数:9
相关论文
共 40 条
[31]  
SMITH SW, 1994, COMPUT APPL BIOSCI, V10, P671
[32]   Various types of HIV mixed infections in Cameroon [J].
Takehisa, J ;
Zekeng, L ;
Ido, E ;
Mboudjeka, I ;
Moriyama, H ;
Miura, T ;
Yamashita, M ;
Gürtler, LG ;
Hayami, M ;
Kaptué, L .
VIROLOGY, 1998, 245 (01) :1-10
[33]   High diversity of HIV-1 subtype F strains in Central Africa [J].
Triques, K ;
Bourgeois, A ;
Saragosti, S ;
Vidal, N ;
Mpoudi-Ngole, E ;
Nzilambi, N ;
Apetrei, C ;
Ekwalanga, M ;
Delaporte, E ;
Peeters, M .
VIROLOGY, 1999, 259 (01) :99-109
[34]  
Vandamme AM, 1999, DRUGS, V57, P337
[35]   Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes [J].
Velazquez-Campoy, A ;
Todd, MJ ;
Vega, S ;
Freire, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (11) :6062-6067
[36]   Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients [J].
Vergne, L ;
Peeters, M ;
Mpoudi-Ngole, E ;
Bourgeois, A ;
Liegeois, F ;
Toure-Kane, C ;
Mboup, S ;
Mulanga-Kabeya, C ;
Saman, E ;
Jourdan, J ;
Reynes, J ;
Delaporte, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (11) :3919-3925
[37]   Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa [J].
Vidal, N ;
Peeters, M ;
Mulanga-Kabeya, C ;
Nzilambi, N ;
Robertson, D ;
Ilunga, W ;
Sema, H ;
Tshimanga, K ;
Bongo, B ;
Delaporte, E .
JOURNAL OF VIROLOGY, 2000, 74 (22) :10498-10507
[38]   Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: A sentinel site for monitoring HIV genetic diversity in the United States [J].
Weidle, PJ ;
Ganea, CE ;
Irwin, KL ;
Pieniazek, D ;
McGowan, JP ;
Olivo, N ;
Ramos, A ;
Schable, C ;
Lal, RB ;
Holmberg, SD ;
Ernst, JA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (02) :470-475
[39]  
Weidle PJ, 2001, J ACQ IMMUN DEF SYND, V26, P495, DOI 10.1097/00126334-200104150-00017
[40]   Phylogenetic analysis of protease and transmembrane region of HIV type 1 group O [J].
Yang, CF ;
Gao, F ;
Fonjungo, PN ;
Zekeng, L ;
Van der Groen, G ;
Pieniazek, D ;
Schable, C ;
Lal, RB .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (11) :1075-1081